Aurinia Pharmaceuticals Announces Q3 Financial Results Release
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has revealed plans to announce its financial and operational results for the third quarter of the year. This much-anticipated release is set to occur before markets open on November 7, 2024. The management team at Aurinia is eager to share essential updates and insights regarding the company's performance during this period.
Conference Call and Webcast Information
On the same day, Aurinia will host a conference call and audio webcast at 8:30 am ET. The session will provide stakeholders with a detailed review of the quarterly results and include a comprehensive business update. This interactive platform will allow participants to engage with the company's leadership as they navigate through the highlights of the quarter.
Accessing the Webcast
Investors and interested parties can join the audio webcast by following the link provided by the company. It will serve as an effective means for shareholders to stay informed about Aurinia's strategic direction. For those who prefer to join via telephone, they can dial (800) 715-9871 for domestic calls and +1 (646) 307-1963 for international calls. During the call, the conference ID 6251719 or the company’s name is required for entry.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is dedicated to addressing significant medical needs within the realm of autoimmune diseases. As a fully integrated biopharmaceutical company, it aims to provide valuable therapies to individuals afflicted by these challenging conditions. The introduction of LUPKYNIS (voclosporin) marked a significant milestone for the company, as it became the first FDA-approved oral medication specifically designed for adult patients suffering from active lupus nephritis. Furthermore, Aurinia continues to advance its pipeline, which includes AUR200, a promising new therapy tailored for autoimmune diseases that addresses both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand).
Frequently Asked Questions
What date is Aurinia Pharmaceuticals releasing their Q3 results?
Aurinia Pharmaceuticals will release their Q3 financial results before markets open on November 7, 2024.
How can I access the conference call?
You can join the conference call by dialing (800) 715-9871 for domestic callers or +1 (646) 307-1963 for international calls, using the conference ID 6251719.
What is LUPKYNIS?
LUPKYNIS (voclosporin) is an FDA-approved oral therapy specifically for adult patients with active lupus nephritis developed by Aurinia Pharmaceuticals.
What other treatments is Aurinia developing?
Aurinia is also developing AUR200, a new potential therapy targeting autoimmune diseases that engages both BAFF and APRIL.
When is the conference call scheduled?
The conference call is scheduled for November 7, 2024, at 8:30 am ET.
